Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Alzheimer pill gives hope to Down's cases

Jeremy Laurance
Friday 26 March 1999 01:02 GMT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

DOCTORS HAVE discovered a potential treatment for the mental disabilities caused by Down's syndrome. A drug used in Alzheimer's disease has also been shown to improve the functioning of adults with the condition.

The treatment, which has so far been tried in only four patients, raises questions about the propriety of using drugs to treat disability. Parents of Down's syndrome children who elected for cosmetic surgery for their offspring to disguise the almond eyes and flattened nose associated with the condition have been accused of encouraging discrimination.

The four patients, aged from 24 to 67, were treated with the drug Aricept for an average of nine months. Aricept was launched in Britain a couple of years ago as a treatment for Alzheimer's disease and has been shown to delay the cognitive decline associated with the disease by about six months.

Down's syndrome is caused by a disorder of the chromosomes that cannot be corrected. The effects, especially in older people, are similar to dementia and two of the four patients already had early signs. However, all four showed improvement in communication, attention span and mood with use of the drug. Beneficial effects were seen within the first three months of treatment.

The researchers, from Duke University Medical School in North Carolina, United States, who report their findings in The Lancet, admit their study is too small to justify widespread treatment of Down's syndrome with Aricept - Eisai-Pfizer's brand-name version of donepezil. But they say the findings justify a larger trial.

There are about 30,000 people with Down's syndrome in Britain and there is widespread opposition to measures to disguise its presence. However, Carol Boys, director of the Down's Syndrome Association, said a drug that boosted functioning would be worth trying.

"The key issue is whether people consent to it. So long as people give consent, and these are adults we are talking about, we would have no objection."

When some families of Down's children chose cosmetic surgery it provoked an outcry. However, Ms Boys said that the issue of a new drug treatment was quite different. "If it improves the outcome for Down's syndrome people, that is quite different from disguising a disability."

Bert Massy, director of the Royal Association of Disability and Rehabilitation, said: "Disability is a normal part of humanity and the way to cope is to be proud of your disability and not to seek cures, because most don't work and most of the problems suffered by disabled people are the result of the attitudes of society.

"On the other hand, the way to enjoy life is to have as much autonomy as possible. Nobody should be forced to take the treatment if they don't want to but some will like it if it improves their functioning."

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in